TCR2 Therapeutics is an immuno-oncology company that has pioneered a novel class of T cell therapies for solid tumors and blood cancers that utilize the full signaling power of complete T cell receptors (TCR) without the need for HLA-matching. TCR2's proprietary multi-format TRuC platform reprograms the natural TCR complex to elicit rapid killing of cancer cells with long persistence and low cytokine release. The company has demonstrated superior activity against several tumor targets in preclinical models compared to CAR T cells and will advance its lead solid tumor program TC-210 targeting mesothelin into the clinic in 2018. TCR2 was founded in 2015 by renowned German immunologist Dr. Patrick Baeuerle and backed with a $44.5M Series A financing led by MPM Capital and F2 Ventures. With a world-class team of immunotherapy experts and entrepreneurs, the company is located in the heart of Kendall Square in Cambridge, MA.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/21/18 | $125,000,000 | Series B |
6 Dimensions Capital Alexandria Real Estate Equities ArrowMark Partners Curative Ventures Haitong International Securities Hillhouse Capital Group Lucion Group Mirae Asset Venture Investment Redmile Group Sirona Capital Syno Capital | undisclosed |
